Selumetinib Plus RAI in Differentiated Thyroid Cancer Selumetinib Plus RAI in Differentiated Thyroid Cancer

Might the addition of selumetinib to adjuvant radioactive iodine offer any advantages in the treatment of high-risk differentiated thyroid cancer?Journal of Clinical Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news